Beta-Glucanase Market to Surpass $912 Million by 2036 as Immune Health Awareness Rises

Demand for Sustainable Functional Ingredients Gains Momentum Across Global Food and Pharma Sectors

Mar. 12, 2026 at 2:08pm

Got story updates? Submit your updates here. ›

The global Beta-Glucanase Market is projected to reach $912 million by 2036, expanding at a 6.3% CAGR, driven by rising consumer awareness of immune health and cardiovascular risk management. Yeast-derived and soluble beta-glucanase formats are in high demand, with the health and dietary supplements sector leading application growth.

Why it matters

The expansion of the beta-glucanase market reflects a broader shift toward preventative healthcare and 'clean-label' functional ingredients. As consumer interest in immune resilience and heart health surges, suppliers must adapt to evolving regulatory frameworks and buyer requirements around traceability and clinical substantiation.

The details

Beta-Glucanase, a bioactive ingredient derived from yeast, cereal grains, and fungi, has gained significant traction due to EFSA and FDA-recognized claims regarding cholesterol reduction and heart health. The market is characterized by a preference for established, highly bioavailable formats that integrate seamlessly into existing manufacturing lines. Yeast-derived sources and soluble functionality account for the largest market shares.

  • The global Beta-Glucanase Market was valued at $495 million in 2026.
  • The market is projected to reach $912 million by 2036, expanding at a 6.3% CAGR.

The players

Cargill Inc.

A global life sciences giant supplying the nutraceutical sector.

Kerry Group Plc

An Ireland-based company focused on high-purity extraction.

Koninklijke DSM N.V.

A Netherlands-based life sciences company.

Tate & Lyle Plc

A UK-based company specializing in enzyme production.

Angel Yeast Co Ltd

A Chinese company with expertise in commercial-scale yeast production.

Got photos? Submit your photos here. ›

What they’re saying

“The central procurement challenge today is not product availability, but supplier qualification and traceability. Buyers consolidating volumes around yeast face concentration risks. Executives who delay formalizing supplier diversification strategies will find their cost structures exposed as regulatory enforcement cycles intensify.”

— Nandini Roy Choudhury, Principal Consultant at FMI

What’s next

Investment should prioritize capacity expansion in China and India to capture incremental demand before supply concentration shifts pricing power. Product teams must also align formulations with evolving EU, US FDA, and Asia-Pacific regulatory thresholds to maintain global market access.

The takeaway

The growth of the beta-glucanase market reflects a broader industry shift toward science-backed functional ingredients that support preventative healthcare and 'clean-label' consumer preferences. Suppliers must adapt to evolving regulatory frameworks and buyer requirements around traceability and clinical substantiation to capitalize on this trend.